LCQ908 + Placebo

Phase 3Completed

1 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Familial Chylomicronemia Syndrome (FCS)

Conditions

Familial Chylomicronemia Syndrome (FCS)

Trial Timeline

Jul 1, 2012 → May 1, 2014

NCT ID

NCT01514461

About LCQ908 + Placebo

LCQ908 + Placebo is a phase 3 stage product being developed by Novartis for Familial Chylomicronemia Syndrome (FCS). The current trial status is completed. This product is registered under clinical trial identifier NCT01514461. Target conditions include Familial Chylomicronemia Syndrome (FCS).

What happened to similar drugs?

5 of 20 similar drugs in Familial Chylomicronemia Syndrome (FCS) were approved

Approved (5) Terminated (4) Active (13)

✅EvolocumabAmgenApproved

✅evolocumabAmgenApproved

✅AnakinraSwedish Orphan BiovitrumApproved

✅Colesevelam hydrochloride film-coated tablets + PlaceboSanofiApproved

✅PraluentSanofiApproved

🔄SHR-1209 ;placebo + SHR-1209 ;placebo + SHR-1209 ;placeboJiangsu Hengrui MedicinePhase 3

🔄Rosuvastatin 20mg + PlaceboAstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01811472	Phase 2	Completed	Jun 1, 2013	Sep 1, 2014	Non-alcoholic Fatty Liver Disease (NAFLD)
NCT01514461	Phase 3	Completed	Jul 1, 2012	May 1, 2014	Familial Chylomicronemia Syndrome (FCS)
NCT01387958	Phase 2	Terminated	Jul 1, 2011	Feb 1, 2012	Hepatitis C
NCT01146522	Phase 1/2	Completed	May 1, 2010	Oct 1, 2011	Hyperlipoproteinemia

Competing Products

20 competing products in Familial Chylomicronemia Syndrome (FCS)

See all competitors

Product	Company	Stage	Hype Score
Bromocriptine Mesilate + Placebos	Towa Pharmaceutical	Phase 1/2	32
SHR-1209	Jiangsu Hengrui Medicine	Phase 2	31
SHR-1209 ;placebo + SHR-1209 ;placebo + SHR-1209 ;placebo	Jiangsu Hengrui Medicine	Phase 3	40
Rosuvastatin 20mg + Placebo	AstraZeneca	Phase 3	40
rosuvastatin calcium + rosuvastatin calcium + rosuvastatin calcium	AstraZeneca	Phase 3	40
Rosuvastatin + Placebo	AstraZeneca	Phase 3	40
Rosuvastatin 20mg	AstraZeneca	Phase 3	40
AZD0780 + Placebo	AstraZeneca	Phase 3	44
Anacetrapib + Placebo for anacetrapib	Merck	Phase 3	40
Statins and Ezetimibe	Merck	Pre-clinical	22
Comparator: niacin (+) laropiprant (MK0524A) + Comparator: placebo	Merck	Phase 3	32
MK-0524A + MK-0524A	Merck	Phase 1	21
Enlicitide Decanoate + Placebo	Merck	Phase 2/3	45
Inclisiran + Placebo	Novartis	Phase 3	40
DFV890	Novartis	Phase 2	35
Canakinumab	Novartis	Phase 2	35
Inclisiran Sodium for injection + Placebo + Placebos	Novartis	Phase 3	40
Inclisiran	Novartis	Phase 3	44
Inclisiran + Placebo	Novartis	Phase 3	40
Fluvastatin	Novartis	Phase 3	40